Injecting support into Unilife
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
More experts are coming around to the upside potential of Unilife Corporation (UNS), with Foster Stockbroking initiating coverage on the stock with a “buy” recommendation following a site visit to its Pennsylvania plant.
Unilife, which is an Uncapped 100 stock, develops one-use pre-filled syringes that have been described by the stockbroker as being a “game-changer” for the injectable devices industry.
The company’s business model is also a cut above most as Unilife is forecast to generate strong operating margins of around 30% to 40% that is backed by long-dated contracts of over 10 years.
A business like this should be trading on a price-earnings multiple premium of around 25 times, according to Foster.
Management is believed to be close to announcing its first commercial order for the syringe and Foster has a price target of $1.50.
The stock, which is dual listed in the US and Australia, is trading flat at 63.5 cents this morning on the ASX.
Call 1300 880 160
Start a chat
Schedule a call
